Management of Patients with Castration‑resistant Metastatic Prostate Cancer

Česká verzia

Authors: D. Ondruš ¹; M. Ondrušová ^2,3
Authors place of work: I. onkologická klinika LF UK a Onkologického ústavu sv. Alžbety, Bratislava, Slovenská republika ¹; Vysoká škola zdravotníctva a sociálnej práce sv. Alžbety, Bratislava, Slovenská republika ²; Ústav experimentálnej onkológie SAV, Bratislava, Slovenská republika ³
Published in the journal: Klin Onkol 2015; 28(1): 24-29
Category: Původní práce
doi: https://doi.org/10.14735/amko201524

Summary

Prostate cancer belongs to the most common malignant tumors in males. Almost in all patients in advanced stage, disease progression occurs despite of castration therapy. Initial treatment of metastatic disease is androgen deprivation therapy. In the case of castration‑resistant disease development in asymptomatic patients, it is a combination of abiraterone acetate plus prednisone and in symptomatic patients docetaxel with prednisone are considered gold standards at the present time. The aim of therapy must be assurance of adequate quality of life, pain reduction and survival improvement. The paper presents an overview of current castration‑resistant metastatic prostate cancer treatment.

Key words:
castration‑resistant prostate cancer – androgen deprivation – chemotherapy

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
29. 12. 2014

Accepted:
8. 1. 2015

Zdroje

1. Safaei Diba Ch, Pleško I (eds). Incidencia zhubných nádorov v Slovenskej republike 2008. Bratislava: Národný onkologický register SR, NCZI 2014.

2. Ondrušová M, Ondruš D. Karcinóm prostaty – vývoj incidencie a mortality na Slovensku v porovnaní so zahraničím. Onkológia (Bratisl.) 2013; 8(1): 29– 31.

3. Obertová J. Prehľad liečby kastračne rezistentného karcinómu prostaty (CRPS). Onkológia (Bratisl.) 2012; 7(4): 257– 262.

4. Čapoun O. Novinky v léčbě kastračně rezistentního karcinomu prostaty. Urol Praxi 2012; 13(3): 101– 110.

5. Mottet N, Bellmunt J, van den Bergh RCN et al (eds). EAU Guidelines on prostate cancer – update April 2014. Arnhem: European Association of Urology 2014: 172.

6. Bishr M, Lattouf JB, Gannon PO et al. Updates on therapeutic targets and agents in castration‑resistant prostate cancer. Minerva Urol Nefrol 2011; 63(2): 131– 143.

7. Hotte SJ, Saad F. Current management of castrate‑resistant prostate cancer. Curr Oncol 2010; 17 (Suppl 2): S72– S79.

8. Petrylak D. Hormone‑ refractory prostate cancer: new horizons. Rev Urol 2003; 5 (Suppl 6): S54– S58.

9. Barilla R, Andrašina I. Nové možnosti a pohľad na liečbu kastračne rezistentného karcinómu prostaty. Onkológia (Bratisl.) 2012; 7(1): 45– 51.

10. Hanuš M, Matoušková M. Nové možnosti léčby kastračně rezistentního karcinomu prostaty. Remedia 2012; 22(3): 254– 262.

11. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone‑resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14(6): 1756– 1764.

12. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone‑ refractory prostate cancer: results of the cancer and leukemia group B 9 182 study. J Clin Oncol 1999; 17(8): 2506– 2513.

13. Heidenreich A, Bastian PJ, Bellmunt J et al (eds). Guidelines on prostate cancer. Arnhem: European Association of Urology 2012: 164.

14. Tannock IF, de Wit R, Berry WR et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502– 1512.

15. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513– 1520.

16. Kliment J. Súčasné možnosti liečby hormonálne rezistentného karcinómu prostaty. Klin Urol 2007; 3(2): 63– 68.

17. Mardiak J. Chemoterapia hormonálne refraktérneho karcinómu prostaty. Onkológia (Bratisl.) 2007; 2(1): 32– 36.

18. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration‑resistant prostate cancer progressing after docetaxel treatment: a randomised open‑ label rial. Lancet 2010; 376(9747): 1147– 1154. doi: 10.1016/ S0140- 6736(10)61389- X.

19. Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration‑resistant prostate cancer. Future Oncol 2011; 7(4): 497– 506. doi: 10.2217/ fon.11.23.

20. Galsky MD, Small EJ, Oh WK et al. Multi‑institutional randomited phase trial of the eoptiolone B analog ixabepilone (BMS‑ 247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23(7): 1439–1446.

21. Beardsley EK, Saad F, Eigl B et al. A phase II study of patupilone in patients (pts) with metastatic castration‑resistant prostate cancer (HRCP) who have progressed after docetaxel. J Clin Oncol 2009; 27 (Suppl): abstr. 5139.

22. Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double‑blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate‑ refractory prostate cancer progressing after prior chemotherapy: the SPRARC trial. J Clin Oncol 2009; 27(32): 5431– 5438. doi: 10.1200/ JCO.2008.20.1228.

23. Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone‑ refractory prostate cancer with antigen‑ loaded dendritic cells. J Clin Oncol 2000; 18(23): 3894– 3903.

24. Schellhammer PF, Chodak G, Whitmore JB et al. Lower baseline prostate‑ specific antigen is associated with a greater overall survival benefit from sipuleucel‑ T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 2013; 81(6): 1297– 1232. doi: 10.1016/ j.urology.2013.01.061.

25. Kelly WK, Halabi S, Carducci MA et al. A randomized, double‑blind, placebo‑ controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone and bevacizumab in men with metastatic castration‑resistant prostate cancer (mCRCP): survival results of CALGB 90401. Clin Oncol 2010; 28 (Suppl): abstr. LBA4511.

26. Nabhan C, Lestingi TM, Galvez A et al. Erlotinib has moderate single‑agent activity in chemotherapy‑ naive castration‑resistant prostate cancer: final results of a phase II trial. Urology 2009; 74(3): 665– 671. doi: 10.1016/ j.urology.2009.05.016.

27. Lin AM, Rini BI, Derynck MK et al. A phase I trial of docetaxel/ estramustin/ imatinib in patients with hormone‑ refractory prostate cancer. Clin Genitourin Cancer 2007; 5(5): 323– 328.

28. Saad F, de Bono JS, Haqq CM et al. Abiraterone acetate plus low‑dose prednisone has a favorable safety profile, improves survival and produces PSA a radiographic responses in metastatic castration‑resistant prostate cancer progressing after docetaxel based chemotherapy: results from COU‑ AA‑ 301, a randomized, double‑blind, placebo controlled, phase III study. J Urol 2011; 185: e283.

29. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364(21): 1995– 2005. doi: 10.1056/ NEJMoa1014618.

30. Kliment J. Abiraterón v liečbe metastázujúceho kastračne rezistentného karcinómu prostaty. Onkológia (Bratisl.) 2014; 9(2): 127– 130.

31. Fizazi K, Scher H, Molina A et al. Abiraterone acetate for treatment of metastatic castration‑resistant prostate cancer: final overall survival analysis of the COU‑ AA‑ 301 randomised, double‑blind, placebo controlled phase 3 study. Lancet Oncol 2012; 13(10): 983– 992. doi: 10.1016/ S1470‑ 2045(12)70379‑ 0.

32. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostatae cancer without previous chemotherapy. N Engl J Med 2013; 368(2): 138–148. doi: 10.1056/ NEJMoa1209096.

33. Scher H, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367(13): 1187– 1197.

34. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371(5): 424– 433. doi: 10.1056/ NEJMoa1405095.

35. Tomášek J. Enzalutamid (Xtandi^®) – nová šance pro pacienty s kastračně refrakterním karcinomem prostaty. Klin Onkol 2014; 27(1): 69– 70.

36. Sartor AO, Heinrich D, Helle SI et al. Radium‑ 223 chloride impact on skeletal‑related events in patients with castration‑resistant prostate cancer (CRCP) with bone metastases: a phase III randomized trial (ALSYMPCA). J Clin Oncol 2012; 30 (Suppl 5): abstr. 9.

37. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium‑ 223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369(3): 213– 223. doi: 10.1056/ NEJMoa1213755.

38. Saad F. Management of castration‑resistant prostate cancer: a global approach. Curr Oncol 2012; 19 (Suppl 3): S32– S36. doi: 10.3747/ co.19.1299.

39. Katolická J. Sekvence léčby a sledování pacienta s metastatickým kastračně rezistentním karcinomem prostaty. Urol List 2012; 10(4): 41– 44.

40. Dellis A, Papatsoris AG. Denosumab as a promising novel bone‑ targeted agent in castration resistant prostate cancer. Expert Opin Biol Ther 2014; 14(1): 7– 10. doi: 10.1517/ 14712598.2013.840582.

41. Marenčák J. Kastračne rezistentný karcinóm prostaty. Klin Urol 2013; 9(1): 17– 22.